Vermorken Jan B
Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
Recent Results Cancer Res. 2017;206:137-147. doi: 10.1007/978-3-319-43580-0_10.
When deciding how to treat patients with squamous cell carcinoma of the head and neck (SCCHN), several factors have to be taken into account: disease factors, patient factors, treatment factors, and the wish of the patient. This symposium article is summarizing the information on HPV (p16) in the context of decision making in SCCHN patients with locoregionally advanced disease and those with recurrent/metastatic disease. The literature data suggest that HPV(p16) has prognostic significance, both in locoregionally advanced disease (in particular, in oropharynx cancer) and in recurrent/metastatic disease, while there are only limited data on its predictive significance. Results of HPV (p16) testing should not change management outside clinical trials.
在决定如何治疗头颈部鳞状细胞癌（SCCHN）患者时，必须考虑几个因素：疾病因素、患者因素、治疗因素以及患者的意愿。这篇专题文章总结了在局部晚期疾病和复发/转移性疾病的SCCHN患者决策背景下，关于人乳头瘤病毒（HPV，p16）的信息。文献数据表明，HPV（p16）在局部晚期疾病（特别是口咽癌）和复发/转移性疾病中均具有预后意义，而关于其预测意义的数据有限。HPV（p16）检测结果在临床试验之外不应改变治疗方案。
